MIN 117
Alternative Names: MIN-117; Wf-516; WF516Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Developer Minerva Neurosciences
- Class Analgesics; Antidepressants; Oxadiazoles; Piperidines; Small molecules
- Mechanism of Action 5-HT1A serotonin receptor antagonists; Alpha 1 adrenergic receptor antagonists; Dopamine plasma membrane transport protein antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin plasma membrane transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pain
- Discontinued Major depressive disorder
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Pain in USA
- 24 Feb 2021 MIN 117 is still in phase II trials for Major depressive disorder in Bulgaria, Finland, Poland and USA (Minerva Neurosciences pipeline, February 2021)
- 31 Dec 2020 Discontinued - Phase-II for Major depressive disorder in Latvia, Bulgaria, USA, Finland, Poland (PO)